Intuitive Surgical, Inc. (ISRG) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Intuitive Surgical, Inc. (ISRG)

ISRG 535.00

-1.2%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: semi_infinite who wrote (269)	10/18/2017 3:42:03 PM
From: IceHawk	Read Replies (1) of 438

TransEnterix not 'in the same league' as Intuitive Surgical, says Citi Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next